Geron (P/C Chart, news, volatility) saw a big move last Friday on news the FDA cleared the way for the company’s embryonic stem cell-based therapy clinical trials. Today, shares are up a dime to $8 and a new 52-week high. 24K calls traded. Feb 7.5 and Feb 10 calls are the most actives, with 17,700 traded ahead of an important Feb 9 presentation at the BIO-CEO conference. ISEE Sentiment data says 66 percent of the calls traded on the ISE are opening customer buy orders.
